icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
AMaRC 18-02 - STUDY TITLE: A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma (IRIL)

STATUS

Actively recruiting

 

CURRENT ENROLMENT

58 patients

Recruitment updated as of June 2022

 

STUDY DESIGN

Prospective, multicentre, open label trial, phase II study 

 

CORRELATIVE STUDIES

Blood and bone marrow samples will be collected as part of the trial to assess the immunological, epigenetics and molecular profile 

 

TRIAL PRINCIPAL INVESTIGATOR

Professor Hang Quach

 

TIME FRAME

2019 – 2023

 

PARTICIPANTS

Newly diagnosed multiple myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant 

 

SITE LOCATIONS